Multiple vascular factors play an important role in angiogenesis, with vascular endothelial growth factors and receptors (VEGF-VEGFRs) among the most potent angiogenic systems1 in promoting the growth of solid organ malignancies.2 Therefore, anti-VEGF-VEGFR therapies have become the standards of care (SoC) for several solid malignant conditions including colorectal cancer, renal cancer, hepatocellular cancer and ovarian cancer.3 This evidence concerns the gene VEGFA and ovarian cancer.